SEARCH

SEARCH BY CITATION

References

  • 1
    Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother 2010; 65 (Suppl 3): iii35iii44.
  • 2
    Cainzos M. Review of the guidelines for complicated skin and soft tissue infections and intra-abdominal infections–are they applicable today? Clin Microbiol Infect 2008; 14 (Suppl 6): 918.
  • 3
    Martinez R, Reyes S, Lorenzo MJ, Menendez R. Impact of guidelines on outcome: the evidence. Semin Respir Crit Care Med 2009; 30: 172178.
  • 4
    Merlino JI, Malangoni MA. Complicated skin and soft-tissue infections: diagnostic approach and empiric treatment options. Cleve Clin J Med 2007; 74 (Suppl 4): S21S28.
  • 5
    Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm DF, Nathwani D. Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 2003; 22: 406419.
  • 6
    Eron LJ, Lipsky BA, Low DE, Nathwani D, Tice AD, Volturo GA. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother 2003; 52 (Suppl 1): i3i17.
  • 7
    Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; 41: 13731406.
  • 8
    Nathwani D. New antibiotics for the management of complicated skin and soft tissue infections: are they any better? Int J Antimicrob Agents 2009; 34 (Suppl 1): S24S29.
  • 9
    May AK, Stafford RE, Bulger EM et al. Treatment of complicated skin and soft tissue infections. Surg Infect (Larchmt) 2009; 10: 467499.
  • 10
    Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis 2007; 57: 713.
  • 11
    Talan DA, Krishnadasan A, Gorwitz RJ et al. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin Infect Dis 2011; 53: 144149.
  • 12
    Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Surg Infect (Larchmt) 2005; 6: 283295.
  • 13
    Nathwani D, Moitra S, Dunbar J, Crosby G, Peterkin G, Davey P. Skin and soft tissue infections: development of a collaborative management plan between community and hospital care. Int J Clin Pract 1998; 52: 456460.
  • 14
    World Health Organization. International Classification of Diseases (ICD) 10th Revision (2007 version). Geneva, Switzerland: World Health Organization, 2007.
  • 15
    Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 (Suppl 4): iv41iv51.
  • 16
    Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis 2008; 46: 647655.
  • 17
    Edelsberg J, Berger A, Weber DJ, Mallick R, Kuznik A, Oster G. Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol 2008; 29: 160169.
  • 18
    Hook EW, III, Hooton TM et al. Microbiologic evaluation of cutaneous cellulitis in adults. Arch Intern Med 1986; 146: 295297.
  • 19
    Swartz MN. Cellulitis. N Engl J Med 2004; 350: 904912.
  • 20
    Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38: 16731681.
  • 21
    Gyssens IC, Dryden M, Kujath P et al. A randomized trial of the efficacy and safety of sequential intravenous/oral moxifloxacin monotherapy versus intravenous piperacillin/tazobactam followed by oral amoxicillin/clavulanate for complicated skin and skin structure infections. J Antimicrob Chemother 2011; 66: 26322642.
  • 22
    Wilcox MH, Corey GR, Talbot GH, Thye D, Friedland D, Baculik T. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 (Suppl 4): iv53iv65.
  • 23
    US Food and Drug Administration. Acute Bacterial skin and skin structure infections: Developing drugs for treatment. Guidance for industry. 2010.
  • 24
    Moran GJ, Krishnadasan A, Gorwitz RJ et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355: 666674.
  • 25
    Zervos MJ, Freeman K, Vo L et al. Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients. J Clin Microbiol 2012; 50: 238245.
  • 26
    Zilberberg MD, Shorr AF, Micek ST et al. Epidemiology and outcomes of hospitalizations with complicated skin and skin-structure infections: implications of healthcare-associated infection risk factors. Infect Control Hosp Epidemiol 2009; 30: 12031210.